Cognition Therapeutics, Inc.
Biotechnology ResearchNew York, United States11-50 Employees
Cognition Therapeutics, Inc. is a clinical-stage biotechnology company focused on neurodegenerative diseases. It builds on roughly twenty years of mechanistic and translational research to develop small-molecule therapies aimed at preserving brain synapses before irreversible neuron loss occurs. Its lead candidate, CT1812, also known as zervimesine, is an oral therapy developed to address conditions such as dementia with Lewy bodies and Alzheimer's disease, with the goal of slowing disease progression. The organization emphasizes work in an underserved area of age-related neurodegeneration, seeking treatments that are accessible to patients and caregivers. Headquartered in Purchase, New York, Cognition Therapeutics operates as a small to mid-sized company in the biotechnology research sector. It continues to share clinical data at scientific meetings and has reported biomarker results from the Phase 2 SHINE study in mild-to-moderate Alzheimer's disease, illustrating ongoing evaluation of CT1812.
1-888-653-2347 
support@leadiq.com 
